Literature DB >> 21944002

Targeted therapy in refractory thyroid cancer.

Martin Schlumberger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21944002     DOI： 10.1016/S0959-8049(11)70190-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  2 in total

Review 1.  Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.

Authors:  Cosimo Durante; Alessandra Paciaroni; Katia Plasmati; Fabiana Trulli; Sebastiano Filetti
Journal:  Endocrine       Date:  2013-04-14       Impact factor: 3.633

2.  Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.

Authors:  Ying Wang; Zhigang Hu; Weiyuan Ma; Yong Niu; Jingwei Su; Lingxiang Zhang; Pengxin Zhao
Journal:  Invest New Drugs       Date:  2020-11-27       Impact factor: 3.850
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.